疏风解毒胶囊联合三联雾化吸入治疗慢性阻塞性肺疾病急性加重期临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R563

基金项目:


Clinical Study on Combination Use of Shufeng Jiedu Capsules and Triple Inhaled Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察疏风解毒胶囊联合三联雾化吸入治疗慢性阻塞性肺疾病急性加重期(AECOPD) 的临 床疗效。方法:将90例AECOPD患者按随机数字表法分为观察组、对照组各45例。2组患者入院后均给予基 础治疗,对照组加用特布他林+布地奈德+乙酰半胱氨酸三联雾化吸入治疗,观察组在对照组基础上联合疏风 解毒胶囊治疗。连续治疗7 d后比较2组临床疗效、中医证候评分、血清炎症因子[白细胞介素-6(IL-6)、肿 瘤坏死因子-α (TNF-α)、超敏C-反应蛋白(hs-CRP)] 及肺功能[第1秒用力呼气容积(FEV1)、用力肺活 量(FVC)、FEV1/FVC比值] 水平。结果:观察组总有效率为95.56%,对照组为77.78%,组间比较,差异有 统计学意义(P<0.05)。治疗后,2 组中医证候评分均较治疗前降低(P<0.05),且观察组评分低于对照 组(P<0.05)。治疗后,2组血清hs-CRP、IL-6、TNF-α水平均较治疗前降低(P<0.05),且观察组上述各项 指标水平均低于对照组(P<0.05)。治疗后,2组FEV1、FVC、FEV1/FVC水平均较治疗前升高(P<0.05),且 观察组上述各项指标水平均高于对照组(P<0.05)。结论:疏风解毒胶囊联合三联雾化吸入治疗AECOPD可提 高临床疗效,有效减轻机体炎症反应,改善肺功能及中医证候。

    Abstract:

    Abstract:Objective:To observe the clinical effect of the combination use of Shufeng Jiedu Capsules and triple inhaled therapy on acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods: A total of 90 AECOPD patients were assigned to the observation group and the control group according to the random number table method,with 45 cases in each group. The two groups were given basic treatment after admission; the control group was additionally given triple inhaled therapy of Terbutaline, Budesonide and Acetylcysteine, and the observation group was additionally treated with Shufeng Jiedu Capsules based on the treatment of the control group. After the two groups were treated for seven days, the clinical effects, traditional Chinese medicine (TCM) syndrome scores, and the levels of serum inflammatory factors [interleukin-6 (IL-6), tumor necrosis factor- α (TNF- α) and hypersensitive C-reactive protein (hs-CRP)] and of lung function indexes [forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and ratio of FEV1/FVC] were compared between the two groups. Results: The total effective rate was 95.56% in the observation group and 77.78% in the control group, the difference being significant (P<0.05). After treatment,the TCM syndrome scores in both groups were reduced when compared with those before treatment (P<0.05), and the above scores in the observation group were lower than those in the control group (P<0.05). After treatment, the levels of serum hs-CRP, IL-6 and TNF- α in both groups were down-regulated when compared with those before treatment (P<0.05),and the above three levels in the observation group were lower than those in the control group (P<0.05). After treatment, the levels of FEV1, FVC and FEV1/FVC in the two groups were up-regulated when compared with those before treatment (P<0.05), and the above three levels in the observation group were higher than those in the control group (P<0.05). Conclusion:The combination use of Shufeng Jiedu Capsules and triple inhaled therapy can enhance the clinical effect on AECOPD, effectively reduce the inflammatory responses and improve the lung function and TCM syndromes.

    参考文献
    相似文献
    引证文献
引用本文

余鸿艳,陈道挺.疏风解毒胶囊联合三联雾化吸入治疗慢性阻塞性肺疾病急性加重期临床研究[J].新中医,2024,56(22):58-62

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2024-11-28
  • 出版日期:
文章二维码